Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0638-0355 in adults with overweight or obesity
2026-526797-16-00Phase 2Authorised
- Sponsor
- Novo Nordisk
- Start
- Oct 2026
- Modality
- Small Molecules, Peptides
- Countries
- 2
01
Overview
Phase 2 trial of NNC0638-0355 in obesity and Overweight (2 arms), sponsored by Novo Nordisk. Primary endpoint: Relative change in body weight from baseline to week 26. Planned start Oct 2026; status: authorised.
02
Drugs
NNC0638-0355
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2026-526797-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526797-16-00.